Geoffrey Varty

sanofi-aventis, St. Louis, MO, United States 
"Geoffrey Varty"
Mean distance: 17.5 (cluster 17)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Griebel G, Pichat P, Boulay D, et al. (2016) The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports. 6: 35320
Hodgson RA, Mullins D, Lu SX, et al. (2014) Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior. European Journal of Pharmacology. 730: 157-63
Griebel G, Pichat P, Pruniaux MP, et al. (2012) SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents. Pharmacology, Biochemistry, and Behavior. 102: 203-14
Duffy RA, Morgan C, Naylor R, et al. (2012) Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacology, Biochemistry, and Behavior. 102: 95-100
Lu SX, Higgins GA, Hodgson RA, et al. (2011) The anxiolytic-like profile of the nociceptin receptor agonist, endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide (SCH 655842): comparison of efficacy and side effects across rodent species. European Journal of Pharmacology. 661: 63-71
Harris JM, Neustadt BR, Zhang H, et al. (2011) Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones. Bioorganic & Medicinal Chemistry Letters. 21: 2497-501
Corboz MR, Rivelli MA, McCormick KD, et al. (2011) Pharmacological characterization of a novel α2C-adrenoceptor agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N'-methylurea (compound A). The Journal of Pharmacology and Experimental Therapeutics. 337: 256-66
Black MD, Stevens RJ, Rogacki N, et al. (2011) AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology. 215: 149-63
Hodgson RA, Hyde LA, Guthrie DH, et al. (2011) Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination. Pharmacology, Biochemistry, and Behavior. 98: 181-7
Rogacki N, Lopez-Grancha M, Naimoli V, et al. (2011) The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology, Biochemistry, and Behavior. 98: 405-11
See more...